{"id":"lenalidomide-po-25mg","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Neutropenia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"15-30","effect":"Anemia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Constipation"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Neuropathy"},{"rate":"5-15","effect":"Thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of IKZF1 and IKZF3 proteins. This results in enhanced immune cell activation, increased IL-2 and TNF-α production, and direct anti-proliferative effects on tumor cells. It also has anti-angiogenic properties that inhibit new blood vessel formation in tumors.","oneSentence":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:21.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Myelodysplastic syndromes with deletion 5q"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT06664411","phase":"PHASE2","title":"Pola-ZR2P in Previously Untreated DLBCL","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":80},{"nctId":"NCT06665217","phase":"PHASE2","title":"G-Pola-ZLP in Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2025-09-24","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02911142","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-03","conditions":"Primary Effusion Lymphoma, B-Cell Neoplasm","enrollment":17},{"nctId":"NCT06409702","phase":"PHASE4","title":"Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-06-12","conditions":"Newly Diagnosed, High Risk, MRD","enrollment":59},{"nctId":"NCT01054196","phase":"PHASE1, PHASE2","title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2010-08","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT04939844","phase":"PHASE2","title":"REST - Replacing Steroids in the Transplant Ineligble","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-06-29","conditions":"Multiple Myeloma","enrollment":51},{"nctId":"NCT06549335","phase":"PHASE2","title":"Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"Follicular Lymphoma","enrollment":66},{"nctId":"NCT06503263","phase":"PHASE2","title":"Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-08-30","conditions":"Diffuse Large B-cell Lymphoma","enrollment":240},{"nctId":"NCT06454968","phase":"PHASE2","title":"Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-06-20","conditions":"Marginal Zone Lymphoma","enrollment":45},{"nctId":"NCT04164368","phase":"PHASE2","title":"Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-10-22","conditions":"Double Expressor Lymphoma","enrollment":67},{"nctId":"NCT05477797","phase":"NA","title":"Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-02-16","conditions":"Progression Free Survival, Overall Survival, Maintenance","enrollment":420},{"nctId":"NCT05058755","phase":"NA","title":"Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-09-17","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":62},{"nctId":"NCT06176729","phase":"PHASE2","title":"Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients","status":"RECRUITING","sponsor":"Yan Zhang, MD","startDate":"2023-10-24","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT02843074","phase":"PHASE2","title":"Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-09-21","conditions":"Multiple Myeloma","enrollment":53},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04480099","phase":"PHASE2","title":"Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-07-29","conditions":"Peripheral T-cell Lymphoma","enrollment":96},{"nctId":"NCT05899621","phase":"","title":"A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":"Follicular Lymphoma","enrollment":332},{"nctId":"NCT03001804","phase":"","title":"Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-06-30","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT04941937","phase":"PHASE2","title":"Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM","status":"UNKNOWN","sponsor":"Juan Du","startDate":"2022-01-27","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05182957","phase":"PHASE2","title":"Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-14","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":40},{"nctId":"NCT04922567","phase":"PHASE2","title":"Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Peripheral T-Cell Lymphoma, Lenalidomide, CHOP","enrollment":289},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT05497102","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-11-08","conditions":"Multiple Myeloma","enrollment":58},{"nctId":"NCT02575144","phase":"PHASE3","title":"GEM-CLARIDEX: Ld vs BiRd","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2015-09","conditions":"Multiple Myeloma","enrollment":286},{"nctId":"NCT01578954","phase":"PHASE1","title":"Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06-28","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04287660","phase":"PHASE3","title":"Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-10-19","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04842487","phase":"PHASE2","title":"R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-10","conditions":"DLBCL","enrollment":80},{"nctId":"NCT04842318","phase":"PHASE4","title":"Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-03-01","conditions":"Follicular Lymphoma","enrollment":789},{"nctId":"NCT00478959","phase":"PHASE2","title":"Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-12","conditions":"Hodgkin Disease","enrollment":30},{"nctId":"NCT00460031","phase":"PHASE2","title":"Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2006-09-01","conditions":"Prostate Cancer","enrollment":34},{"nctId":"NCT04435743","phase":"","title":"Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-11-01","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":1000},{"nctId":"NCT04432402","phase":"NA","title":"Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-14","conditions":"Diffuse Large B Cell Lymphoma","enrollment":124},{"nctId":"NCT03367143","phase":"PHASE2","title":"Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-12","conditions":"Diffuse Large B-Cell Lymphoma Refractory","enrollment":39},{"nctId":"NCT03908138","phase":"PHASE4","title":"RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-03-30","conditions":"Hematologic Neoplasms, Multiple Myeloma, Efficacy","enrollment":120},{"nctId":"NCT00928486","phase":"PHASE3","title":"A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-04-28","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT04152577","phase":"PHASE4","title":"R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-05","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT02060656","phase":"PHASE2","title":"Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2013-09","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":92},{"nctId":"NCT04063189","phase":"PHASE2","title":"Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-03-21","conditions":"Multiple Myeloma in Relapse","enrollment":100},{"nctId":"NCT03715309","phase":"PHASE2","title":"R2 in the Treatment of Follicular Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-11-01","conditions":"Follicular Lymphoma","enrollment":115},{"nctId":"NCT03715296","phase":"","title":"Lenalidomide Based Immunotherapy in the Treatment of DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-10-18","conditions":"Diffuse Large B Cell Lymphoma","enrollment":200},{"nctId":"NCT02986451","phase":"PHASE2","title":"Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2016-12","conditions":"Relapse/Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT01724177","phase":"PHASE2","title":"A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-11-12","conditions":"Adult T-Cell Leukemia-Lymphoma","enrollment":26},{"nctId":"NCT02371590","phase":"PHASE2","title":"Lenalidomide and Obinutuzumab for Previously Untreated CLL","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2018-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT03208218","phase":"PHASE1","title":"Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2016-08-17","conditions":"Healthy, Male","enrollment":42},{"nctId":"NCT01133743","phase":"PHASE2","title":"Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT02371577","phase":"PHASE2","title":"Evaluation of the Immune Restoration Potential Of Lenalidomide","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2017-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":""},{"nctId":"NCT00885508","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q","status":"UNKNOWN","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2009-02","conditions":"Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT00837031","phase":"PHASE2","title":"Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-02","conditions":"Metastatic Pancreatic Cancer","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lenalidomide PO (25mg)","genericName":"Lenalidomide PO (25mg)","companyName":"University Hospital, Lille","companyId":"university-hospital-lille","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting pro-inflammatory cytokine production. Used for Multiple myeloma, Myelodysplastic syndromes with deletion 5q, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}